Brand Intelligence Graph
Company Overview
About BrightHeart
BrightHeart is a medical AI company developing prenatal diagnostic tools for detecting congenital heart defects (CHD) — the most common birth defect globally — through standard obstetric ultrasound. The company raised €11 million ($12 million) in Series A financing in January 2026 and achieved five FDA clearances in 2025 ahead of US commercial launch, with distribution through GE HealthCare's Voluson ultrasound platform.
Business Model & Competitive Advantage
BrightHeart's AI detects over 96% of congenital heart defects in prenatal ultrasound — dramatically outperforming standard-of-care detection rates, which miss 30-50% of CHDs in routine obstetric scans. CHDs affect approximately 1 in 100 births globally, and those detected prenatally are far more likely to receive timely cardiac surgery with better outcomes than those detected after birth. BrightHeart's clinical impact is therefore direct and measurable.
Competitive Landscape 2025–2026
GE HealthCare's Voluson platform has a global installed base of hundreds of thousands of ultrasound machines used in obstetric care. By integrating BrightHeart's AI as a native feature of Voluson, the company gains distribution to existing users without requiring hospitals to adopt new hardware or establish separate software procurement processes. This embedded distribution model is highly capital-efficient for a medical device software company at Series A stage.
Key Differentiators
Emerging Innovator
BrightHeart is an emerging player bringing innovative solutions to the MedTech market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Emulate
Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the m
Saluda Medical
Saluda Medical is a commercial-stage medical device company that has pioneered closed-loop neuromodulation therapy for chronic pain management. Headquartered in Macquarie Park, Australia (with US oper
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
10x Genomics
10x Genomics was founded in 2012 in Pleasanton, California by Serge Saxonov, Ben Hindson, and Kevin Ness. The company developed the Chromium platform for single-cell RNA sequencing (scRNA-seq), enabli
ConcertAI
ConcertAI is a Boston-based company that combines artificial intelligence with real-world oncology data to accelerate cancer drug development and improve patient outcomes. Its platform integrates mult
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
Compare BrightHeart with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from BrightHeart? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim BrightHeart Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention BrightHeart vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →